Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005

Research output: Contribution to journalReview articlepeer-review

Abstract

Dengue is the most important arboviral disease world-wide with an estimated 400 million annual infections. Dengvaxia™ is a live attenuated tetravalent vaccine recently licensed for dengue seropositive individuals aged 9–45 years. There is great need for a dengue vaccine that could be given to dengue-naïve individuals and very young children. To that end, the U.S. NIH developed a live attenuated tetravalent dengue vaccine using an iterative approach evaluating the safety, infectivity, and immunogenicity of different candidates. This approach identified poor candidates who were then discarded from further evaluation. Each of the components of the tetravalent vaccine formulation is able to replicate to very low titer, inducing a homotypic immune response to each. The immune response elicited by the tetravalent vaccine is balanced, without immunodominance of one component. The vaccine was licensed by several manufacturers for development, including the Instituto Butantan which initiated a Phase 3 efficacy trial.

Original languageEnglish (US)
Pages (from-to)79-87
Number of pages9
JournalCurrent Opinion in Virology
Volume43
DOIs
StatePublished - Aug 2020

ASJC Scopus subject areas

  • Virology

Fingerprint Dive into the research topics of 'Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005'. Together they form a unique fingerprint.

Cite this